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Dengue fever (DF) is the most common viral disease 
transmitted by the arthropods.1 Dengue fever manifests as 
flu like illness affecting all age groups including infants, 
children and adults. Dengue hemorrhagic fever (DHF) is a 
life threatening complication of dengue characterized by 
high fever, hemorrhagic phenomena, thrombocytopenia and 
sometimes circulatory failure.2 Early diagnosis is essential, 
based mainly on history, physical examination and 
laboratory investigations. There is mortality rate of 1-5% in 
untreated cases and in less than 1% with treatment. However 
with severe disease the mortality rate reaches to 26%.3  
Dengue and DHF are fast emerging as a global health 
problems. 4 Dengue is endemic in more than 110 countries. 
It affects 50 to 100 million people worldwide a year with 
half a million hospitalizations and almost 12,500-25,000 
deaths.5 The incidence of dengue has increased 30 folds 
between 1960 and 2010. Factors responsible for dengue’s 
spread include explosive population growth, unplanned 
urban overpopulation with inadequate public health systems 
and poor vector control.  
 
Epidemiology in Pakistan 
Dengue virus is now endemic in Pakistan with a peak 
incidence in the post monsoon period. Introduction of a new 
serotype (DEN-3) and a genotypic shift of endemic serotype 
(DEN-2) are the most probable factors for the recent out-
break of DHF in this region.6 First confirmed outbreak of 
DHF in Pakistan was reported from Karachi in 1994 and in 
the following year an epidemic of DF occurred in 
Baluchistan. 7,8 Later, a large outbreak occurred in 2006 in 
Karachi.9 In 2011, more than 15,000 cases have been 
recorded in Lahore alone with a high mortality rate. 
 
Transmission 
Dengue fever virus (DENV) is an RNA virus of the 
family Flaviviridae; genus Flavivirus.  Most are transmitted 
by arthropods  (mosquitoes or ticks). There are four 
serotypes of the virus; these are referred to as DENV-1, 
DENV-2, DENV-3 and DENV-4. All four serotypes can 
cause the full spectrum of disease. Infection with one 
serotype is believed to produce lifelong immunity to that 
serotype but only short term protection against the others.10 
The severe complications on secondary infection occur 
particularly if someone previously exposed to one serotype 
then contracts another serotype.11 In Pakistan the genotypes 
DENV-2 and DENV-3 were found to be prevalent.  
The reservoirs for Dengue are both man and mosquito 
(Aedes aegypti). Man acts as a host. The viremia among 
humans builds up high titers two days before the onset of the 
fever and lasts 5–7 days after the onset of the fever. It is 
only during these two periods that the vector species get 
infected. Thereafter, the humans become dead-end for 
transmission. Aedes aegypti mosquito generally acquires the 
virus while feeding on the blood of an infected person and 
transmits disease to another non infected person. It is 
primarily a daytime feeder and lives around human 
habitation. 12 The mosquitoes breed in stored, exposed, water 
collection systems and other dark places.  
 
Pathogenesis 
The pathogenesis of DHF is poorly understood. Abnormal 
immune response has the major role in its pathogenesis. 
Production of cytokines or chemokines: These include 
C3a, C5a, TNF-α, IL-2, IL-6, IL-10, Interferon-α and 
Histamine 13  
Activation of T lymphocytes: The level of T-cell activation 
is enhanced particularly in secondary dengue infection. 
Many dengue specific T cells have low affinity for other, 
probably previously encountered serotypes. Profound T cell 
activation may suppress or delay viral elimination leading to 
higher level of viral loads and thus enhanced symptoms seen 
in DHF.   
Antibody mediated immune response: It has been 
observed that certain strains of dengue virus complex with 
non neutralizing antibodies and enter the mononuclear cells. 
Infected monocytes release vasoactive mediators resulting in 
increased vascular permeability and hemorrhagic 
manifestations that characterize DHF and dengue shock 
syndrome (DSS). Halstead described the antibody dependent 
enhancement upon the second infection with dengue virus.14 
Antibodies directed against dengue virus also cross react 
with human platelets and endothelial cells.15 Increased 
platelet destruction, platelet dysfunction and endothelial cell 
dysfunction are also the result of cross reactivity between 
these antibodies to platelet gylcoproteins and endothelial 
cells.  
Passively transferred Antibodies: Antibodies, 
predominantly of the IgG1 subclass, are the only 
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immunological substances known to be transferred from 
mother to fetus.16 The fact that infants fail to develop 
clinical dengue illnesses until around 6 months of age 
accords with the presence of broadly reactive dengue 
neutralizing antibodies in their mothers’ serum samples and 
the protection afforded by passively transferred dengue 
antibodies. 17 
 
Table 1: Clinical and Laboratory findings in Dengue 
fever 
Course of 
illness 
Febrile 
Phase 
Critical 
Phase 
Recovery 
Phase 
Days of 
Illness 1-3 4-5 6-10 
Clinical 
findings Dehydration 
Bleeding/Sh
ock 
Organ 
impairment 
Reabsorption 
Hematocrit N ↑↑ N 
Platelet 
count N ↓↓ N 
Viremia Present Absent Absent 
Serology Negative Positive Positive 
 
Mechanism o various manifestations: Studies have shown 
that median age of dengue patients has decreased now and 
younger patients may be more susceptible. Severity of 
disease depends on virus strain, previous infection, host 
genetics and age. Epidemic potential is dependent on level 
of viremia, infectivity and virus serotype. DHF risk is the 
greatest for DEN-2; followed by DEN-3, DEN-4 and DEN-
1, respectively.18 Various factors underlie the clinical 
manifestations of DHF.  
1. Plasma leakage: The plasma leakage is due to the 
increased vascular permeability induced by several 
mediators such as C3a and C5a during the acute febrile 
stage and this is more pronounced during toxic stage. The 
evidence of plasma leakage includes hemoconcentration, 
hypoproteinemia/hypoalbuminemia, pleural effusion, ascites 
and shock. Sometimes the rising hematocrit may not be 
evidenced because of either severe bleeding or early 
intravenous fluid administration. 
2. Bleeding tendency: The bleeding diathesis is caused 
by:  
 Vasculopathy 
 Thrombocytopenia/ platelet dysfunction  
 Coagulopathy 
a. Vasculopathy: A positive tourniquet test indicating the 
increased capillary fragility is found in the early febrile 
stage. It may be a direct effect of dengue virus as it 
appears in the first few days of illness during the 
viremic phase. 
b. Thrombocytopenia and platelet dysfunction: 
Thrombocytopenia is almost always present in patients 
with dengue. Patients with DHF usually have platelet 
counts less than 100×109/l. Bone marrow suppression 
combined with increased peripheral destruction of 
platelets during the febrile and early convalescent phase 
of dengue disease are two important factors leading to 
profound thrombocytopenia.19 Thrombocytopenia is 
most prominent during the toxic stage. However, during 
the recovery period, platelet count rises due to return of 
marrow cellularity. In the absence of substantial 
bleeding prophylactic platelet transfusions should be 
avoided to minimize risk of long-term complications. 20 
Platelet dysfunction is another factor leading to 
bleeding. The platelet dysfunction might be the result of 
exhaustion from platelet activation triggered by immune 
complexes containing dengue antigen, absence of 
adenosine diphosphate (ADP) release and impaired 
platelet aggregation response to ADP. An increase in 
plasma-thromboglobulin and platelet factor4, indicating 
increased platelet secretary activity have also been 
observed.  21  
c. Coagulopathy: The coagulopathy associated with 
dengue infections is well described. Several groups 
have noted the presence of plasminogen cross-reactive 
antibodies and fibrinolytic activity during and after 
dengue infection. During the acute febrile stage, mild 
prolongation of the prothrombin time (PT) and partial 
thromboplastin time (APTT), as well as reduced 
fibrinogen levels, have been reported.22 Variable 
reductions in the activities of several coagulation 
factors, including prothrombin, factors V, VII, VIII, IX 
and X, antithrombin and antiplasmin, have also been 
demonstrated. Fibrin degradation product or D-dimer 
may be elevated. Low levels of anticoagulant proteins C 
and S and antithrombin III were found to be associated 
with increasing severity of shock, presumably due to 
plasma leakage. Elevated levels of tissue factor, 
thrombomodulin and plasminogen activator inhibitor-1 
reflect endothelial, platelet and/or monocyte activation 
and may be a secondary response to direct activation of 
fibrinolysis by the dengue virus. Release of heparin like 
substances e.g. heparan sulphate or chondroitin sulfate 
might also contribute to the overall picture.23 
Thrombocytopenia together with these abnormalities 
correlates with overall severity of disease. The 
coagulation abnormalities however are well 
compensated in the majority of patients without 
circulatory collapse.24, 25 
 
Clinical Manifestations 
Clinical course of dengue infection changes as the disease 
progresses. Dengue virus infection may be asymptomatic or 
may cause undifferentiated febrile illness (viral syndrome), 
dengue fever, or dengue hemorrhagic fever including 
dengue shock syndrome (DSS). (Figure1) Various diseases 
(viral/bacterial/parasitic) may mimic dengue fever and 
should be considered in differential diagnosis while 
evaluating a patient with suspected dengue. Incubation 
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period is 4–6 days (range 3–14 days). After an incubation 
period full spectrum of disease develops and is followed by 
3 phases. (Table 1) 
 Febrile phase  
 Critical phase 
 Recovery phase 
Febrile Phase: After an incubation period, various non-
specific, symptoms are seen. These include headache, 
backache and general malaise. Typically, the onset of DF is 
sudden with a sharp rise in temperature (usually lasting 5–7 
days, occasionally accompanied by chills). Other 
manifestations include retro-orbital pain, photophobia, 
backache, and pain in the muscles and joints/bones, 
anorexia, constipation, colicky pain and abdominal 
tenderness, dragging pain in the inguinal region, sore throat 
and general depression. These symptoms usually persist 
from several days to a few weeks and vary markedly in 
frequency and severity. These clinical features are 
indistinguishable between DF and DHF. 26,27 Mild 
hemorrhagic manifestations like positive tourniquet test or 
petechiae and mucosal membrane bleeding may be seen in 
DF and DHF. Vaginal and gastrointestinal bleeding may 
also occur during this phase but are not common. 28 The 
findings of an enlarged and tender liver are more suggestive 
of DHF  
The earliest abnormality in the complete blood count is a 
progressive decrease in total white cell count and this with 
previously mentioned clinical features should alert the 
physician to a high index of suspicion of dengue. 
Critical Phase: The critical phase occurs towards the late 
febrile phase (usually between 3rd to 5th day of illness but 
may go up to 7th day) when a rapid drop in temperature may 
coincide with an increase in capillary permeability in some 
patients. In other viral infections, the patient’s condition 
improves as the temperature subsides, but the contrary 
happens in DHF. At this point the patient will either become 
better if no or minimal plasma leak occurs, or worse if a 
critical volume of plasma is lost. The critical phase lasts 
about 24-48 hours. Varying circulatory disturbances can 
develop. In less severe cases, these changes are minimal and 
transient. Many of these patients recover spontaneously, or 
after a short period of fluid or electrolyte therapy. In more 
severe forms of plasma leakage, the patients may sweat, 
become restless, have cool extremities and prolonged 
capillary refill time. The pulse rate increases, diastolic blood 
pressure increases and the pulse pressure narrows. 
Abdominal pain, persistent vomiting, restlessness, altered 
conscious level, clinical fluid accumulation, mucosal bleed 
or tender enlarged liver are the clinical warning signs of 
severe dengue or high possibility of rapid progression to 
shock. 29,30  
The patient can progress rapidly to profound shock and 
death if prompt fluid resuscitation is not instituted. 
Thrombocytopenia and hemoconcentration (evidenced by a 
raised hematocrit (HCT) are usually detectable before the 
subsidence of fever and the onset of shock. The HCT level 
correlates well with plasma volume loss and disease 
severity. However, the levels of HCT may be equivocal 
when there is frank hemorrhage, early and excessive fluid 
replacement or untimely HCT determinations. Leucopenia 
with relative lymphocytosis, clotting abnormalities, 
elevation of transaminases [typically the level of AST is 
about 2-3 times the level of ALT], hypoproteinemia and 
hypoalbuminemia are usually observed in this phase.    
Recovery (convalescent) Phase: After 24-48 hours of 
defervescence, plasma leakage stops and is followed by 
reabsorption of extravascular fluid. Patient’s general 
condition improves, appetite returns, gastrointestinal 
symptoms disappear, hemodynamic status stabilizes and 
diuresis ensues. Some patients may have a rash or 
generalized pruritus. Bradycardia and electrocardiographic 
changes are not uncommon during this stage. During this 
phase, HCT level stabilizes or drops further due to 
hemodilution following reabsorption of extravascular fluid. 
The recovery of platelet count is typically preceded by 
recovery of white cell count. It is very important that every 
probable or confirmed case of dengue fever must be 
reported.   
 
 
Figure 1: Clinical Course of Dengue virus Infection 
 
Dengue hemorrhagic fever  
The features of Dengue Hemorrhagic fever include:  
•Fever: Acute onset of fever of 2-7 days duration  
•Hemorrhagic manifestations, shown by any of the 
following:   
o Petechiae , ecchymosis or purpura  
o Bleeding from mucosa, gastrointestinal tract, 
injection sites, or other locations.  
o Positive tourniquet test   
• Thrombocytopenia  
• Objective evidence of plasma leakage due to increased 
vascular permeability shown by any of the following:  
o Rising hematocrit/hemoconcentration  
o Evidence of plasma leakage such as pleural 
effusion, ascites or hypoproteinemia 
/hypoalbuminemia  
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DHF is further divided in four grades. Grade III and IV are 
classified as dengue shock syndrome (DSS)  
 
Dengue shock syndrome  
Criteria for dengue hemorrhagic fever as above with signs of 
shock: Tachycardia, cool extremities, delayed capillary 
refill, weak pulse, hypotension, lethargy or restlessness 
which may be a sign of reduced brain perfusion  
 
Expanded Dengue Syndrome  
In 2011 WHO guidelines the term of expanded dengue 
syndrome has been used to include unusual manifestations 
of dengue infection. These include neurological, hepatic, 
renal and other isolated organ involvement. These could be 
explained as a complication of severe profound shock or 
associated with underlying host conditions/diseases or co-
infections.  
 
Laboratory Diagnosis  
Laboratory investigations of dengue fever include disease 
monitoring laboratory tests and diagnostic tests. 
1. Diagnostic  Tests:  Laboratory confirmatory tests 
include:  
 Antibody detection (serology) 
 PCR 
 Detection of dengue virus protein (NS1 antigen) 
 
Dengue Serology: 
IgM Detection (by ELISA) 
IgM detection by ELISA is the most widely used method for 
diagnosis of dengue fever. Once IgM is detectable, it rises 
quickly and peaks at about 2 weeks after onset of symptoms 
and it wanes to undetectable levels by 60 days. However in 
some patients it may persist for more 90 days. A positive 
result thus has to be interpreted and correlated cautiously 
with the clinical picture. If IgM dengue test is the only test 
available then establishing a negative IgM early in illness 
and demonstrating a positive serology later will be essential 
to exclude false negative results. In one study, IgM was 
detected in only 55% of patients with primary dengue 
infections between day 4-7 onset of fever, and it became 
positive in 100% of the patients after day 7. However, in 
secondary dengue infections, IgM was detected in only 78% 
of patients after day 7.31 In another study, 28% of secondary 
dengue infections were undiagnosed when IgM was the only 
test performed. 32,33 
 
IgG detection by ELISA   
In primary and secondary dengue infection, dengue IgG was 
detected in 100% of patients after day 7 of onset of fever. 
Therefore dengue IgG is recommended if dengue IgM is still 
negative after day 7 with the negative IgG in the initial test 
sample. 
IgM/IgG ratio  
The IgM/IgG ratio is used to distinguish primary infection 
from secondary dengue infection. A dengue virus infection 
is defined as primary if IgM/IgG ratio is greater than 1.2, or 
as secondary if the ratio is less than 1.2.  
Rapid Diagnostic Tests (RDT)  
Simple rapid tests such as the strip assays 
(immunochromatography test) are available for qualitative 
detection of dengue IgM and IgG. The yield of rapid tests 
was shown to be higher when samples were collected later 
in the convalescent phase of infection, with good specificity 
and could be used when ELISA test were not available.34 
However the result had to be interpreted in the clinical 
context because of false positive and negative results. 35,36 It 
is recommended that the dengue IgM be done by ELISA test 
after a rapid test, to confirm the status. 
 
Other Tests: 
Dengue viremia in patients is short, typically occurs 2–3 
days prior to the onset of fever and lasts for four to seven 
days of illness. During this period the dengue virus, its 
nucleic acid and circulating viral antigen can be detected. 
During the early stages of the disease (up to six days of 
onset of illness), virus isolation, viral nucleic acid or antigen 
detection can be used to diagnose infection. At the end of 
acute phase of infection, immunological tests are the 
methods of choice for diagnosis. 
 
Polymerase chain reaction (PCR)  
Molecular tests such as the reverse transcriptase – 
polymerase chain reaction (RT- PCR) are useful for the 
diagnosis of dengue infection in the early phase (< 5 days of 
illness). It has a good sensitivity in the first 5 days of 
disease, but reduces after this, following the disappearance 
of the viremia. An additional advantage of RT- PCR is the 
ability to determine dengue serotypes. 37,38 It is useful in 
early phase of illness and its use is particularly considered 
for in-patients who present with diagnostic challenges in the 
early phase of illness.  
 
Non-structural protein-1 (NS1 antigen)  
The NS1 gene product is a glycoprotein produced by all 
flaviviruses and is essential for replication and viability of 
the virus. The protein is secreted by mammalian cells but 
not by insect cells. NS1 antigen appears as early as Day 1 
after the onset of the fever and declines to undetectable 
levels by 5–6 days. Hence, tests based on this antigen can be 
used for early diagnosis. This antigen is present in high 
concentrations in the sera of dengue infected patients during 
the early phase of the disease. 39,40 The detection rate is 
much better in acute sera of primary infection (75%-97.3%) 
when compared to the acute sera of secondary infection 
(60% 70%). 41 The sensitivity of NS1 antigen detection 
drops from day 4-5 of illness onwards and usually becomes 
undetectable in the convalescence phase. 42 
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Laboratory Findings in DF  
 The laboratory findings during an acute DF episode of 
illness are as follows:  
• Total WBC is usually normal at the onset of fever; then 
leucopenia develops with decreasing neutrophil count and 
lasts throughout the febrile period.  
• Platelet counts are usually normal, as are other components 
of the blood clotting mechanism. Mild thrombocytopenia 
(100,000 to 150 000 cells/mm3) is common and about half 
of all DF patients have platelet count below 100,000 
cells/mm3, but severe thrombocytopenia (<50 000 
cells/mm3) is rare. 43  
• Mild hematocrit rise (10%) may be found as a 
consequence of dehydration associated with high fever, 
vomiting, anorexia and poor oral intake.  
• Serum biochemistry is usually normal but liver AST levels 
may be elevated.  
 
Laboratory Findings in DHF:  
• The WBC count may be normal or with predominant 
neutrophils in the early febrile phase. Thereafter, there is a 
drop in the total number of white blood cells and 
neutrophils, towards the end of the febrile phase. A relative 
lymphocytosis with increased atypical lymphocytes is 
commonly observed by the end of the febrile phase and into 
convalescence. These changes are also seen in DF.  
• The platelet counts are normal during the early febrile 
phase. A mild decrease could be observed thereafter. A 
sudden drop in platelet count to below 100,000 occurs by 
the end of the febrile phase before the onset of shock or 
subsidence of fever. The level of platelet count is correlated 
with severity of DHF. In addition there is impairment of 
platelet function. These changes are of short duration and 
return to normal during convalescence.  
• A rise in hematocrit occurs in all DHF cases, particularly 
in shock cases and is objective evidence of plasma leakage. 
It should be noted that the level of hematocrit may be 
affected by early volume replacement and by bleeding. 
• Thrombocytopenia and hemoconcentration are constant 
findings in DHF. A drop in platelet count to below 100,000 
cells/mm3 is usually found between the 3rd and 10th days of 
illness.  
• Other common findings are hypoproteinemia/ 
hypoalbuminemia (as a consequence of plasma leakage), 
hyponatremia, and mildly elevated serum ALT (=200 U/L) 
with the ratio of AST: ALT > 2.  
• A transient mild albuminuria is sometimes observed.  
• Occult blood is often found in the stool.  
• In most cases, assays of coagulation and fibrinolytic 
factors show reductions in fibrinogen, prothrombin, factor 
VIII, factor XII, and antithrombin III. A reduction in 
antiplasmin (plasmin inhibitor) has been noted in some 
cases. In severe cases with marked liver dysfunction, 
reduction is observed in the vitamin K-dependent factors 
such as factor V, VII, IX and X.  
• Partial thromboplastin time and prothrombin time are 
prolonged in about half and one third of DHF cases 
respectively. Thrombin time is also prolonged in severe 
cases.  
• Hyponatremia is frequently observed in DHF and is more 
severe in shock.  
• Hypocalcemia (corrected for hypoalbuminemia) has been 
observed in all cases of DHF.  
• Metabolic acidosis is frequently found in cases with 
prolonged shock. Blood urea nitrogen is elevated in 
prolonged shock. 
 
2. Disease Monitoring Laboratory Tests:  
Patients of dengue fever require continuous monitoring for 
proper management and following tests along with clinical 
judgment should be carried out serially to monitor the 
response of treatment ant determination of overall prognosis 
of these patients  
 Complete Blood Count (CBC) with particular 
attention to;  
              White blood cell count  
              Hematocrit   
              Platelet count  
 Coagulation tests 
 Liver Function Tests  
Elevated liver enzymes is common and is characterized by 
greater elevation of the AST as compared to the ALT. 44 The 
frequency and degree of elevation of the liver enzymes are 
higher with DHF compared to DF. 
Management: 
There is no specific treatment for DHF. Therapy for DHF is 
wholly symptomatic and aims at controlling the clinical 
manifestations of shock and hemorrhage. Patients who do 
not receive a proper treatment usually die within 12–24 
hours after shock ensues. The most important aspect of 
management of patients with DHF is close observation by 
the attending physicians and nurses with frequent clinical 
and laboratory monitoring. 
Adequate fluid replacement to overcome the plasma 
leakage: It is recommended that patients must take full rest 
and plenty of fluids. During the febrile stage ingestion of 
adequate soft diet and drink is encouraged. For reducing 
fever, frequent sponging and paracetamol are provided. 
Aspirin and nonsteroidal anti-inflammatory drugs such as 
ibuprofen are contraindicated. The patient with suspected 
dengue infection should have daily follow-up at the 
outpatient clinic starting from the third day of fever to 
defervescence for 24 hours approaching the convalescent 
stage. The mortality and morbidity rates of patients with 
DHF can be reduced by early hospitalization and optimal 
supportive care. Prompt and adequate fluid replacement to 
overcome massive plasma leakage is a medical emergency. 
After proper management in the toxic stage for 24– 48 
hours, the fluid in the extravascular space spontaneously 
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returns to the intravascular space. Patients uneventfully 
recover. Good prognostic signs are adequate urine output 
and regaining of appetite.  
Control of bleeding: Some patients whose platelet count is 
reduced markedly may require platelet transfusion to avoid 
bleeding and shock. The risk factors for bleeding include the 
duration of shock, ingestion of aspirin or NSAID, 
administration of large amounts of plasma expanders and the 
improper management in the febrile and toxic stages. The 
Packed red blood cells may be required for patients who 
exhibit massive bleeding. Fresh frozen plasma is indicated 
for patients who have massive bleeding due to 
coagulopathy, or circulatory failure, which does not respond 
to intravenous crystalloid replacement. However, no 
evidence supports the benefit of preventive transfusion of 
platelet concentrate and FFP in patients with DHF, as the 
risk of bleeding is not solely based on the number of platelet 
counts or coagulopathy. 
Immunization: No vaccine is yet available to provide 
protection against dengue fever.  
Future scenario of Dengue in Pakistan  
In Pakistan, the first confirmed outbreak occurred due to 
serotype DV-2 reported in 1994, thereafter, sporadic cases of 
DHF continued to be reported from different parts of the 
country. Analyzing the 2010 post monsoon situation, 
according to leading clinicians, by 2012, around 50 to 60 
million people of Pakistan especially living in Lahore and 
Karachi might get infected with dengue virus. Thus urgent and 
efficient surveillance is required to prevent this catastrophe.45 
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